Back to Search
Start Over
An epitope-specific chemically defined nanoparticle vaccine for respiratory syncytial virus.
- Source :
-
NPJ vaccines [NPJ Vaccines] 2021 Jun 18; Vol. 6 (1), pp. 85. Date of Electronic Publication: 2021 Jun 18. - Publication Year :
- 2021
-
Abstract
- Respiratory syncytial virus (RSV) can cause severe respiratory disease in humans, particularly in infants and the elderly. However, attempts to develop a safe and effective vaccine have so far been unsuccessful. Atomic-level structures of epitopes targeted by RSV-neutralizing antibodies are now known, including that bound by Motavizumab and its clinically used progenitor Palivizumab. We developed a chemically defined approach to RSV vaccine design, that allows control of both immunogenicity and safety features of the vaccine. Structure-guided antigen design and a synthetic nanoparticle delivery platform led to a vaccine candidate that elicits high titers of palivizumab-like, epitope-specific neutralizing antibodies. The vaccine protects preclinical animal models from RSV infection and lung pathology typical of vaccine-derived disease enhancement. The results suggest that the development of a safe and effective synthetic epitope-specific RSV vaccine may be feasible by combining this conformationally stabilized peptide and synthetic nanoparticle delivery system.
Details
- Language :
- English
- ISSN :
- 2059-0105
- Volume :
- 6
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- NPJ vaccines
- Publication Type :
- Academic Journal
- Accession number :
- 34145291
- Full Text :
- https://doi.org/10.1038/s41541-021-00347-y